MX1 and ovarian cancer: Several studies have demonstrated the combination of eribulin and cisplatin to be effective in treating ovarian cancer (A2780) and TNBC (HCC1806 and MX-1) [26], as well as advanced solid tumors (breast, pancreatic, bladder, head and neck, and lung cancer) [25].